Neuroma, Acoustic: Clinical Trials

122 trials for Neuroma, Acoustic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

50 completed, 21 recruiting, 21 unknown, 9 terminated. 44 Not applicable, 31 Phase 2, 9 Phase 1, 5 Phase 3, 4 Early Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable44Completed 20, Recruiting 8, Unknown 7, Withdrawn 5, Terminated 2, Active not recruiting 1, Enrolling by invitation 1
Phase 231Completed 16, Not yet recruiting 4, Terminated 4, Active not recruiting 3, Recruiting 2, Unknown 2
Phase 19Completed 3, Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Suspended 1, Terminated 1
Phase 35Terminated 2, Completed 1, Recruiting 1, Unknown 1
Early Phase 14Completed 2, Recruiting 1, Terminated 1
Phase 42Withdrawn 2

Follow Neuroma, Acoustic: new trials by email Literature Review of Neuroma, Acoustic trials Research Report on Neuroma, Acoustic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Role of ChatGPT in Vestibular Schwannoma Management
Use of chatGPT for 1 week - Vestibular Schwannoma
Not applicableWithdrawnUniversity of Southern California2027-01-012026-01-13
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2Not yet recruitingBeijing Tiantan Hospital2002026-07-182026-07-20
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Panitumumab-IRDye800 - Meningioma, Glioblastoma
Early Phase 1RecruitingEben Rosenthal302026-07-072026-10-16
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
Measuring Vestibular Organ Function With Weak Alternating Current Stimulation
Active transcranial electrical vestibular stimulation (Active EVS), Sham transcranial electrical vestibular stimulation (Sham EVS), Control measurement - Vestibular Disorder, Vestibular Schwannoma
Not applicableEnrolling by invitationAalto University302026-06-082026-07-01
Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery
Oliceridine, Sufentanil - PONV, Cerebellopontine Angle Tumor
Not applicableRecruitingXuanwu Hospital, Beijing1742026-03-252026-05-22
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Vestibular Schwannoma
Enrolling by invitationAkouos, Inc.1002026-03-022026-07-16
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
Auto-captioning Glasses - NF2-related Schwannomatosis
Not applicableCompletedMassachusetts General Hospital182026-02-192026-08-25
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis
Phase 3RecruitingBeijing Tiantan Hospital3642025-10-092026-10-26
3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features
Vestibular Schwannoma
RecruitingShengjing Hospital302025-09-252026-10-16
Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma
No Intervention: Observational Cohort, Structured home-based vestibular telerehabilitation program, CE-marked clinical rotatory chair - Vestibular Schwannoma, Vestibular Schwannomas
Not applicableRecruitingAlbert Torrents Torrero752025-09-012026-01-23
Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma
vestibular schwannoma resection - Vestibular Schwannoma, Unilateral Vestibular Deficit
Not applicableRecruitingMarketa Bonaventurova402025-06-012026-10-22
Early Rehabilitation Using Head Impulse Test for Acute Vestibular Deficit
Experimental treatment: Head movements, Sham treatment: only eye movements - Vestibular Schwannoma, Unilateral Vestibular Deficit
Not applicableRecruitingHospices Civils de Lyon262025-05-132025-05-16
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma
Phase 1 / Phase 2RecruitingAkouos, Inc.272025-01-172026-04-06
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2CompletedReveal Pharmaceuticals Inc.182024-08-152025-12-26
USPIO Enhanced MR Imaging in CNS Tumours (UMIC)
USPIO enhanced MRI - Vestibular Schwannoma, Glioma, Astrocytic
Not applicableRecruitingNorthern Care Alliance NHS Foundation Trust172024-04-262024-08-27
Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery
Vestibular exam - Vestibular Schwannoma, Neurinoma, Acoustic
Not applicableUnknownCentre Hospitalier Universitaire de Besancon202024-02-202024-09-19
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas
Microsurgical resection of VS, Stereotactic radiosurgery, PREHAB - Vestibular Schwannoma
Not applicableRecruitingMedical College of Wisconsin362024-01-222026-03-24

Showing 20 of 122. Sign in to see all of them.

Narrower conditions

Neurofibromatosis 2 (47)  ·  Meningioma (18)  ·  Brain Neoplasms (10)  ·  Ependymoma (10)  ·  Neurilemmoma (8)  ·  Neurofibromatoses (8)  ·  Hearing Loss (7)  ·  Neurofibromatosis 1 (7)  ·  Vestibular Diseases (7)  ·  Glioma (5)  ·  Astrocytoma (4)  ·  Dizziness (4)  ·  Glioblastoma (4)  ·  Neoplasms (4)

Broader conditions

Cranial Nerve Diseases (122)  ·  Cranial Nerve Neoplasms (122)  ·  Ear Diseases (122)  ·  Neoplasms by Histologic Type (122)  ·  Neoplasms, Nerve Tissue (122)  ·  Nerve Sheath Neoplasms (122)  ·  Neuroectodermal Tumors (122)  ·  Neuroendocrine Tumors (122)  ·  Otorhinolaryngologic Neoplasms (122)  ·  Neoplasms, Germ Cell and Embryonal (121)  ·  Nervous System Diseases (121)  ·  Neuroma (121)  ·  Retrocochlear Diseases (121)  ·  Otorhinolaryngologic Diseases (120)  ·  Vestibulocochlear Nerve Diseases (120)

Interventions

Bevacizumab (7)  ·  Radiosurgery (6)  ·  Cochlear Implants (4)  ·  Everolimus (4)  ·  AZD 6244 (3)  ·  Gentamicins (3)  ·  HDAC-42 (2)  ·  Lapatinib (2)  ·  Sirolimus (2)  ·  ((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine (1)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1)  ·  89Zr-bevacizumab (1)  ·  Aspirin (1)  ·  Axitinib (1)

Sponsors

Massachusetts Eye and Ear Infirmary (6)  ·  Massachusetts General Hospital (6)  ·  Beijing Tiantan Hospital (5)  ·  NYU Langone Health (5)  ·  Medical University of Vienna (3)  ·  University Hospital Tuebingen (3)  ·  Akouos, Inc. (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Assistance Publique Hopitaux De Marseille (2)  ·  Central Hospital, Nancy, France (2)  ·  Christoph Arnoldner (2)  ·  FDA Office of Orphan Products Development (2)  ·  Haukeland University Hospital (2)  ·  Henry Ford Health System (2)  ·  Lund University (2)

Countries

United States (59)  ·  France (16)  ·  China (9)  ·  United Kingdom (6)  ·  Austria (5)  ·  Germany (3)  ·  Sweden (3)  ·  Czechia (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Norway (2)  ·  Denmark (1)  ·  Egypt (1)  ·  Finland (1)  ·  Puerto Rico (1)

Top investigators

Ana-Maria Vranceanu, PhD (3)  ·  Matthias A Karajannis, MD, MS (3)  ·  Aaron Tward, MD (2)  ·  D. Bradley Welling, MD, PhD (2)  ·  Fu Zhao (2)  ·  Matthew L Carlson, MD (2)  ·  Pinan Liu (2)  ·  Scott Plotkin, MD (2)  ·  Theodore Nicolaides, MD (2)  ·  Anhua Wu, MD (1)  ·  Antonio Omuro (1)  ·  Ashkan Monfared, MD (1)  ·  Brad Welling, MD, PhD (1)

Results publications

PMID 17917842, PMID 19574236, PMID 19645909, PMID 22027076, PMID 10449559, PMID 11587600, PMID 11710496, PMID 11981398, PMID 12925338, PMID 12943357, PMID 14724495, PMID 15354006, PMID 15519876, PMID 17438254, PMID 17562049, PMID 18607963, PMID 18769654, PMID 19645932, PMID 20592851, PMID 20592852, PMID 20802221, PMID 20851113, PMID 23573135, PMID 24904885, PMID 25745609, PMID 26247776, PMID 26943915, PMID 26976425, PMID 28053986, PMID 28811848, PMID 30355560, PMID 30666464, PMID 31083225, PMID 31511780, PMID 31796939, PMID 32421171, PMID 33737417, PMID 34409538, PMID 34570301, PMID 34667843, PMID 35064449, PMID 35229827, PMID 35925531, PMID 36240730, PMID 36651958, PMID 36809199, PMID 37311055, PMID 37378983, PMID 37440099, PMID 37526718

NIH funding

2017 (1), P30CA006973 (1), P30CA008748 (1), P30CA086862 (1), R01DC003196 (1), R01DC012593 (1), R01DC017425 (1), R44CA261240 (1), U01CA069856 (1)